-
Detailed Analysis Generate Full Report Add to Watchlist
Values as of: 2024-06-26
OSCR:NYE- (USD)
COMMON STOCK | Healthcare Plans |
Last Closing
USD 17.92Change
+0.28 (+1.59)%Market Cap
USD 4.56BVolume
2.27MVerdict
Verdict
Values as of: 2024-06-26
COMMON STOCK | Healthcare Plans |
Last Closing
USD 17.92Change
+0.28 (+1.59)%Market Cap
USD 4.56BVolume
2.27MVerdict
Verdict
Currency: USD
Country : USA
Symbol | Name | Price(Change) | Market Cap |
---|---|---|---|
UNH | UnitedHealth Group Incorporate.. |
+22.82 (+4.69%) |
USD 445.93B |
ELV | Elevance Health Inc |
+6.09 (+1.14%) |
USD 122.56B |
CI | Cigna Corp |
-3.58 (-1.07%) |
USD 96.58B |
CVS | CVS Health Corp |
+0.70 (+1.20%) |
USD 75.60B |
HUM | Humana Inc |
+10.67 (+2.94%) |
USD 42.84B |
CNC | Centene Corp |
-1.07 (-1.59%) |
USD 36.14B |
MOH | Molina Healthcare Inc |
-5.53 (-1.83%) |
USD 17.82B |
NEUE | NeueHealth Inc |
+0.24 (+4.62%) |
USD 0.05B |
Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
---|---|---|---|---|---|
DDOC:F | Global X Telemedicine & D.. | 4.48 % | 0.00 % |
+0.01 (+-0.31%) |
USD 4.76M |
EDOC:SW | Global X Telemedicine & D.. | 4.48 % | 0.00 % |
-0.02 (-0.31%) |
USD 4.55M |
EDOC:LSE | Global X Telemedicine & D.. | 4.04 % | 0.00 % |
-0.01 (-0.31%) |
USD 4.59M |
EDOG:LSE | Global X Telemedicine & D.. | 4.04 % | 0.00 % |
-0.01 (-0.31%) |
USD 0.14M |
FFTY | Innovator IBD® 50 ETF | 0.00 % | 0.80 % |
-0.22 (-0.31%) |
USD 0.09B |
FYC | First Trust Small Cap Gro.. | 0.00 % | 0.70 % |
+0.25 (+-0.31%) |
USD 0.27B |
FYX | First Trust Small Cap Cor.. | 0.00 % | 0.63 % |
+0.78 (+-0.31%) |
USD 0.83B |
KIE | SPDR® S&P Insurance ETF | 0.00 % | 0.35 % |
-0.29 (-0.31%) |
USD 0.73B |
EDOC | Global X Telemedicine & D.. | 0.00 % | 0.00 % |
-0.11 (-0.31%) |
USD 0.05B |
DDOC:XETRA | Global X Telemedicine & D.. | 0.00 % | 0.00 % |
-0.02 (-0.31%) |
USD 5.39M |
Market Performance vs. Industry/Classification (Healthcare Plans) | Market Performance vs. Exchange | ||||||
Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
YTD | |||||||
Capital Gain | 95.85% | 100% | F | 99% | N/A | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | 95.85% | 100% | F | 99% | N/A | ||
Trailing 12 Months | |||||||
Capital Gain | 114.87% | 100% | F | 99% | N/A | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | 114.87% | 100% | F | 99% | N/A | ||
Trailing 5 Years | |||||||
Capital Gain | N/A | N/A | N/A | N/A | N/A | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | N/A | N/A | N/A | N/A | N/A | ||
Average Annual (5 Year Horizon) | |||||||
Capital Gain | 22.94% | 88% | B+ | 86% | B+ | ||
Dividend Return | 22.94% | 88% | B+ | 85% | B | ||
Total Return | N/A | N/A | N/A | N/A | N/A | ||
Risk Return Profile | |||||||
Volatility (Standard Deviation) | 100.22% | 13% | F | 7% | C- | ||
Risk Adjusted Return | 22.89% | 25% | F | 46% | F | ||
Market Capitalization | 4.56B | 22% | F | 75% | C |
Target Price Action | Rating Action | Analyst | Rating | Price | Date |
---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
The stock is trading high compared to its peers median on a price to book value basis.
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
The company had negative total cash flow in the most recent four quarters.
This stock has shown below median earnings growth in the previous 5 years compared to its sector